TNF-related apoptosis-inducing ligand (TRAIL) induces monocytic maturation of both leukemic and normal myeloid precursors via a caspase-dependent pathway

Running title: Maturative effects of TRAIL

Scientific Section Heading: Hematopoiesis

Paola Secchiero¹, Arianna Gonelli¹, Prisco Mirandola¹, Elisabetta Melloni¹, Loris Zama²
Claudio Celeghini¹, Daniela Milani¹ and Giorgio Zauli³

¹Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, Via Fossato di Mortara 66, 44100 Ferrara, Italy;
²Institute of Morphological Sciences, University of Urbino, campus scientifico - località Crocicchia, 61029 Urbino, Italy;
³Department of Human Normal Morphology, University of Trieste, Via Manzoni 16, 34138 Trieste, Italy.

Footnote: This research was supported by C.N.R. and A.I.R.C. funds. Arianna Gonelli is supported by a F.I.R.C. fellowship.

Please send all correspondence to: Paola Secchiero, Ph.D., Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, Via Fossato di Mortara 66, 44100 Ferrara, Italy; Fax: 39-0532-207351; Tel: 39-0532-291574. E-mail: secchier@mail.umbi.umd.edu

Word count: manuscript= 5196; abstract= 234
Abstract

Treatment of the human HL-60 cell line with TNF-related apoptosis-inducing ligand (TRAIL) resulted in rapid (6-24 hours) cytotoxicity associated to progressive maturation of the surviving cells along the monocytic lineage. The occurrence of monocytic maturation was demonstrated by: i) a significant increase of both CD14 and CD11b surface expression, ii) the acquisition of morphological features typical of mature monocytes, and iii) of phagocytic capacity in TRAIL-treated cultures. By using selective pharmacological inhibitors, it was possible to demonstrate that activation of the caspase cascade played a crucial role in mediating both TRAIL cytotoxicity and monocytic maturation of HL-60 cells. Moreover, experiments performed using agonistic polyclonal antibodies, which mimic the interactions between TRAIL and each TRAIL receptor, indicated that TRAIL-R1 was responsible for mediating the TRAIL-induced maturation. Importantly, the maturational effects of TRAIL were observed also in primary normal CD34+ cells, seeded in serum-free liquid cultures for 4-8 days in the presence of SCF + GM-CSF. After treatment with TRAIL for additional 3 days, a significant increase of CD14 and CD11b expression coupled to an increased number of mature monocytes and macrophages was noticed in the absence of cytotoxicity. These data disclose a novel role for TRAIL as a positive regulator of myeloid differentiation. Moreover, the dichotomous effect of TRAIL on malignant cells (early induction of apoptosis and monocytic maturation of the surviving cells) might have important therapeutic implications for the treatment of acute myeloid leukemias.

Corresponding author’s e-mail address: secchier@mail.umbi.umd.edu

Keywords: TRAIL, TRAIL receptors, caspases, maturation, monocytes.
**Introduction**

TNF-related apoptosis-inducing ligand (TRAIL) (1), also known as Apo-2 ligand (2), is a member of the structurally related TNF family of cytokines. A subset of these cytokines, including TNF, CD95L, DR3 ligand (TWEAK) and TRAIL, is known to activate the cell death program (reviewed in 3, 4). These cytokines, also called death ligands, induce apoptosis by activating their cognate surface receptors. These death receptors are members of the TNF receptor super-family and include TNFR1, CD95 (Fas/Apo-1), death receptor (DR)-3, DR-4, DR-5, and DR-6. In particular, TRAIL, which exists as either a type II membrane protein or as a soluble protein (5), specifically binds and induces apoptosis via DR-4 (also known as TRAIL-R1) and DR-5 (also known as TRAIL-R2) (1, 2, 4). The unique feature of TRAIL, with respect to CD95L and TNF-α, is considered its ability to induce apoptosis in a variety of malignant cells, including several of hemopoietic origin (6-11), displaying minimal toxicity on normal cells and tissues (reviewed in 12). The study of Jo et al. raised a cautionary note for the use of TRAIL in human cancer therapy in consideration of the potential toxicity of TRAIL on in vitro cultured human normal hepatocytes (13). A recent study, however, has clarified that recombinant TRAIL prepared for clinical purposes is not toxic either in vivo or in vitro, also when used at very high concentrations (500 µg/ml) (14).

TRAIL induces cell death via recruitment of the adapter molecules FADD (15, 16) and a hierarchical cascade of cysteine preoteases, termed caspases, which are synthesized as proenzymes and activated by cleavage through upstream caspases or by intermolecular auto-proteolysis (17). They can be grouped in three major families: i) the ICE subgroup (caspases 1, 4 and 5) corresponds to proteases involved in both apoptosis and cytokine maturation; ii) the CPP32 subgroup (caspases 3, 6 and 7) includes caspases, which mediate downstream steps of proteolysis with preferential cleavage of the DEVD sequence; iii) caspases 2, 8, 9 and 10, which are characterized by the presence of a long prodomain and are related to events of receptor-dependent initiation of apoptosis (17). Initial studies (15, 16) have outlined the central role of caspase 8 in mediating the apoptotic signal of TRAIL, while a more recent work has demonstrated that caspase 8 and 10 are both recruited by the interaction of TRAIL with either DR-4/TRAIL-R1 or...
DR-5/TRAIL-R2 (18). By inducing proximity between pro-caspase-8 and –10 molecules, which possess weak protease activity, death receptor clustering facilitates trans-proteolysis and consequent activation of the cell death machinery (17, 18).

It should be emphasized that, although TRAIL has potential as an anti-cancer therapeutic, its physiologic role is presumably more complex than merely activating caspase-dependent cell death of cancer cells. In this respect, it has been shown by us and other groups of investigators that TRAIL induces stage of development-specific inhibitory effects on normal immature erythroblasts (19, 20). Moreover, it has been recently shown that caspase activation plays an essential role in the terminal differentiation of human normal erythroblasts (21), disclosing a novel role for caspases in the control of hemopoiesis beside that of mediating apoptotic cell death. Therefore, since very little is still known about possible non-apoptotic functions induced by TRAIL, these data suggest that TRAIL might play different roles in the regulation of normal human hemopoiesis.

The experiments illustrated in this study were designed to investigate the biological activity of TRAIL on myeloid cells in terms of cytotoxicity and/or modulation of maturation along the monocytic lineage. As experimental system, we have chosen the HL-60 myeloblastic leukemia cell line, which can be induced to undergo terminal differentiation along the monocytic and granulocytic lineages by a variety of chemical and biological agents (22-25). Parallel experiments were carried out using primary normal myeloid cells, derived from CD34+ hemopoietic progenitors, to ascertain whether TRAIL exhibited a maturation-inducing activity also on normal myeloid cells.
Materials and Methods

Reagents

Both recombinant Histidine6-tagged (His.) TRAIL and His. control peptide were produced in bacteria and purified by chromatography on Ni²⁺ affinity resin. Each batch of recombinant TRAIL was tested for cytotoxicity on the TRAIL-sensitive Jurkat cell line, as previously described (20, 26). The absence of endotoxin contamination in the recombinant TRAIL preparation (<0,1 endotoxin units/ml) was assessed by Limulus Amoebocyte Lysate (LAL) assay (BioWhittaker, Walkersville, MD).

LPS (Sigma Chemicals, St Louis, MO) and polymyxin B (Calbiochem) were used at the final concentration of 10-100 ng/ml and 10 µg/ml, respectively. LY294002, a pharmacological inhibitor of the PI 3-kinase/Akt signal transduction pathway, was purchased from Calbiochem (La Jolla, CA) and used at the final concentration of 10 µM.

For neutralization experiments, either recombinant TRAIL or the supernatant derived from apoptotic TRAIL-treated HL-60 cultures was pre-incubated with TRAIL-R1-Fc and/or and TRAIL-R2-Fc chimeras, according to the supplier’s instructions (R&D, Minneapolis, MI).

The broad caspase inhibitor Cbz-Val-Ala-Asp (Ome)-fluoromethyl ketone (z-VAD-fmk), the peptide control Cbz-Phe-Ala-fluoromethyl ketone (z-FA-fmk), the selective caspase 8 Cbz-Ile-Glu(Ome)-Thr-Asp(Ome)-CH₂F(z-IETD-fmk) and caspase 9 Cbz-Leu-Glu(Ome)-His-Asp(Ome)-CH₂F (z-LEHD-fmk) inhibitors were from Calbiochem. The activity of most effector caspases (3, 4 and 7) as well as of caspase 1, is blocked by z-VAD-fmk, while z-IETD-fmk and z-LEHD-fmk specifically block the activity of caspase 8 and 9, respectively. All caspase inhibitors were dissolved in DMSO, stocked in aliquots at -20°C, and used at the final concentration of 10-100 µM.

Inhibitor of inducible nitric oxide (NO) synthase (iNOS) N-nitro-L-arginine methyl ester (L-NAME; Calbiochem) was added to the culture medium at a concentration of 0.5 mM.
Cells

HL-60 cell line, an M2/M3 type acute myeloid leukemia (AML), was grown in RPMI (Gibco) supplemented with 10% fetal calf serum (FCS, Gibco) at an optimal cell density of 3x10^5-1.2x10^6 cells/ml. Cell stocks were employed between passages 30 to 65, and were re-established from cryopreserved stock cultures. Cell stocks were routinely monitored for mycoplasma contamination by the gene probe method (Gentile Probe Inc., San Diego, CA).

In some experiments, 24 hours after TRAIL treatment, dead HL-60 cells were removed from the cultures by using the Dead Cell Removal kit (Miltenyi Biotech, Auburn, CA). In other experiments, TRAIL-treated HL-60 cultures were enriched in CD14^+ cells by positive selection using CD14 MicroBeads (Miltenyi Biotech).

Cord blood (CB) specimens, collected according to institutional guidelines, were obtained during normal full-term deliveries. CB mononuclear cells were isolated by density gradient centrifugation (Ficoll/ Histopaque 1077 g/ml). CB CD34^+ cells were then isolated by using a magnetic cell sorting program Mini-MACS and the CD34 isolation kit (Miltenyi Biotech) in accordance with the manufacturer's instructions. The purity of CD34^+ ranged between 90-98%. Myeloid cultures were obtained by seeding CD34^+ cells in X-vivo (BioWittaker) medium, supplemented with nucleosides (10 µg/ml each), 0.5% BSA (fraction V of Chon), 10^{-4} M BSA-adsorbed cholesterol, 10 µg/ml insulin, 200 µg/ml iron-saturated transferrin, 5x10^{-5}M 2-β-mercaptoethanol (all purchased from Sigma), stem cell factor (SCF, 50 ng/ml), granulocyte/macrophage-colony stimulating factor (GM-CSF, 10 ng/ml) (20). All cytokines were purchased from Genzyme (Cambridge, MA). Every three-four days, cultures were demi-populated by removing half volume of the medium, which was substituted with fresh medium supplemented with cytokines, and analyzed for phenotypic expression of myeloid maturative markers. Cells were treated with either control His. peptide or TRAIL, that was typically added between days 4-8 of culture.
Assessment of apoptosis and cell differentiation

After TRAIL-treatments, both cytotoxicity and maturation-inducing activity were assessed. In particular, at different times (1-6 days) post-treatment with TRAIL, samples were analyzed by: (i) counting the total number of viable cells by Trypan blue dye exclusion; (ii) evaluating the degree of apoptosis by propidium iodide (PI) staining and flow cytometry analysis (iii) monitoring cell surface antigen expression by using flow cytometry (for this purpose, surface expression of CD33, CD14, CD15 and CD11b antigens was analyzed); (iv) examining the morphology of the cells by staining with May-Grunwald-Giemsa solution and/or with 4’,6-diamidine-2’-phenylindole dihydrochloride (DAPI) followed by either light or fluorescence microscopy examination, respectively, and by transmission electron microscopy; (v) examining the presence of “nonspecific”, monocyte-associated, esterase (NSE) by cytochemical procedure with the NSE kit (Sigma); (vi) measuring solid particle phagocytosis activity by flow citometry after addition of 5x10⁵/ml FITC-latex microbeads (diameter=2.0 µm, Polyscience, Warrington, PA) to the cells for 2 hours at 37°C, as previously described (27).

Flow cytometry analyses

Apoptosis and surface cellular antigens were analyzed by flow cytometry. For apoptosis detection and quantification, samples containing 2-5x10⁵ cells were harvested by centrifugation at 200 x g for 10 min at 4°C, fixed with cold 70% ethanol for at least 1 hour at 4°C and treated as previously detailed (28). After PI staining, analysis of PI fluorescence was performed by FACScan flow cytometer with the FL2 detector in a linear mode using the Lysis II software (Becton-Dickinson, San José, CA). For quantitative evaluation of apoptosis, the subdiploid (<2n) DNA content was calculated as described (28), and expressed as percentage of apoptotic versus non-apoptotic cells, regardless of the specific cell cycle phase.

In order to examine the presence of surface antigens, aliquots of 0.5x10⁶ cells/experimental point were subjected to single- or multiple-label staining, as described previously (29). In particular, CD33, CD15, CD11b and CD14 expression was analyzed by direct staining with either phycoerythrin (PE)- or fluorescein isothiocyanate (FITC)-
conjugated MoAb (Becton-Dickinson). Non-specific fluorescence was assessed by using isotype-matched controls. The expression of TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4 was analyzed by indirect staining using goat anti-human TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4 polyclonal antibodies (all from R&D System) followed by phycoerythrin (PE)-conjugated rabbit anti-goat IgG (Sigma). Aspecific fluorescence was assessed by using normal goat IgG followed by second layer as above.

In TRAIL-treated cultures, surface antigens and endocytic activity were analyzed in the gated area detecting viable cells, as established according to the PI staining-negative area, and the forward and side scatter intensities established by multi-color analysis. Data collected from 10,000 cells are reported as either percentage of positive cells or mean fluorescence intensity (MFI) values. All analyses were performed by using a FACScan flow cytometer (Becton Dickinson) and the Lysis II software (Becton Dickinson).

**Assays for caspase activity**

The caspase activity was measured in HL-60 cell extracts by using the fluorometric CaspACE assay system (Promega Co., Madison, WI). To determine ICE (Caspase-1) and CPP32 (Caspase-3) protease activities, assays were performed in triplicates in 96-well flat-bottom plates by incubating 10 µg of cell proteins/sample with the specific fluorogenic substrates according to the manufacturer’s instructions. After 1 hour of incubation, the products of reaction were measured by using a plate reader (Victor 1420, Wallac, Freiburg, Germany). Increase in fluorescence was linear over time and extract concentration.

Caspase activation was also monitored by using the CaspACE FITC-VAD-FMK in situ marker (Promega) according to the manufacture’s instructions. This compound is a FITC-conjugate of the cell permeable broad caspase inhibitor VAD-fmk, that can be delivered into the cells where it binds to activated caspase. The bound marker was localized by fluorescence detection and quantified by flow cytometry.
Analysis of TRAIL receptors transcripts

The presence of TRAIL receptor mRNA transcripts was examined by RT-PCR. RNA purification from HL60 and primary myeloid cultures was performed using the SV total RNA isolation system (Promega) following the manufacturer's protocol. Synthesis of first strand cDNA and amplification were performed using the Access RT-PCR system (Promega) and specific primer sets, following the manufacturer's protocol. As a control for DNA contamination, equal amounts of RNA were used for PCR without template retro-transcription. RT-PCR reactions were performed using the following primer sets: TRAIL-R1 (forward: 5’-CTG AGC AAC GCA GAC TCG CTG TCC AC-3’; reverse: 5’-TCC AAG GAC ACG GCA GAG CCT GTG CCA T-3’); TRAIL-R2 (forward: 5’-GCC TCA TGG ACA ATG AGA TAA AGG TGG CT-3’; reverse: 5’-CCA AAT CTC AAA GTA CGC ACA AAC GG-3’); TRAIL-R3 (forward: 5’-GAA GAA TTT GGT GCC AAT GCC ACT G-3’; reverse: 5’-CTC TTG GAC TTG GCT GGG AGA TGT G-3’); TRAIL-R4 (forward: 5’-CTT TTC CGG CGG CGT TCA TGT CCT TC-3’; reverse: 5’-GTT TCT TCC AGG CTG CTT CCC TTT GTA G-3’); β-actin (forward: 5’-TGACGGGGTCACCCACACTGTGCCCATCTA-3’; reverse: 5’-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3’). The resulting PCR products from RT-PCR were resolved on 2% agarose gels and visualized with ethidium bromide.

Statistical analysis

Data were analyzed using the two-tailed, two-sample t-test (Minitab statistical analysis software, State College, PA). Values of $P<0.05$ were considered significant.
Results

**TRAIL induces a rapid cytotoxicity on HL-60 cells coupled to maturation of the surviving cells along the monocytic lineage**

Following treatment with recombinant Histidine6-tagged TRAIL, containing the TRAIL protein fused to a tag of six histidine residues, or with a control Histidine6-peptide (His-Pept.) (26), the extent of apoptosis was determined by PI staining followed by flow cytometry analysis and cell viability was determined by Trypan blue dye exclusion. While cultures treated with the control His-Pept. were indistinguishable from the untreated ones, addition of TRAIL induced a dose-dependent increase of apoptosis (**Figure 1**), accompanied by a drastic decline in the total number of Trypan blue dye-negative viable cells (data not shown).

Phenotypic analysis of untreated and His-Pept.-treated HL60 cells showed a high expression of CD33 and CD15 early myeloid markers, low expression of CD11b late myeloid marker and virtually absent expression (<7%) of CD14 (**Figure 2A**). While CD33 and CD15 antigens were unaffected by TRAIL treatment, a significant ($P<0.01$) subset (39±10% means±SD, $n$ 27 independent experiments) of HL-60 cells surviving to the cytotoxic activity of TRAIL, unexpectedly showed a selective induction of the surface 55-kD glycoprotein CD14 (**Figure 2A**). It should be noticed that CD14 represents an excellent marker of monocytic maturation since it is undetectable on the surface of monocyte precursors and increases dramatically during their differentiation to monocytes (30-32). Surface CD11b, the β2 integrin CR3, is another classical marker of myeloid differentiation that is involved in cell adhesion and also functions as a complement receptor (33). Similarly to CD14, also CD11b expression, present at low MFI in a subset of control HL-60 cells (25±9%, mean+SD, $n$ 12 independent experiments), was significantly ($P<0.01$) increased (58±10%, mean+SD, $n$ 12 independent experiments) upon treatment with TRAIL (**Figure 2A**). It is also remarkable that the induction of CD14 surface antigens by TRAIL was dose-dependent (**Figure 2B**). By dual staining analysis performed with anti-CD14 + anti-CD11b MoAb it was also possible to demonstrate that the two antigens were co-expressed in the same cell populations (data not shown), further suggesting that TRAIL induced the maturation along the monocytic
lineage in at least a sub-population of HL-60 cells. In agreement with previous studies showing that the up-regulation of CD14 and CD11b antigens constitutes a relatively early maturation event which anticipates morphological differentiation (25, 34), we found that both CD14 and CD11b markers were up-regulated already after 24 hours from the addition of TRAIL.

We next investigated whether these phenotypic changes were accompanied by the appearance in culture of cells with monocytic features. Therefore, HL-60 cultures were depleted of the necrotic cells and debris 24 hours after TRAIL treatment, and cultured for additional 2-to-5 days before performing morphological (Figure 3) and cytochemical (NSE) analyses (data not shown). At both light (Figure 3A) and electron (Figure 3B) microscopy, cells with morphological features of the monocytic lineage, such as condensation and cleaving of the nucleus, were hardly detectable in untreated and His-Pept.-treated cultures. On the contrary, by day 3 of TRAIL treatment, cells with monocytic features represented a significant percentage of the surviving cell population, ranging from 20 to 50%.

The specificity of the pro-apoptotic and maturational effects of TRAIL was next demonstrated combining different approaches. To completely rule out the effect of potential contaminating LPS in the TRAIL preparations, cells were treated in presence of polymyxin, an inhibitor of LPS. The TRAIL-mediated cytotoxicity (Figure 4A) and upregulation of surface CD14 (Figure 4B) were unaffected by co-treatment of HL-60 cells with polymyxin. On the other hand, polymyxin completely abrogated the ability of LPS (100 ng/ml) to induce a small increase of surface CD14. The specificity of the effect was confirmed by preincubation of TRAIL with TRAIL-R1-Fc or TRAIL-R2-Fc chimeric proteins, that abrogated the TRAIL-mediated maturational effects (Figure 4A), without exhibiting by themselves any effect on the expression of surface markers in HL-60 cells (Figure 4B). In addition, we considered the possibility that apoptosis of a large proportion of cells, as consequence of TRAIL treatment, could leave a subpopulation undergoing differentiation in response to signals derived from apoptosing cells, related to the stress of the elimination of large proportions of cells. Therefore, to evaluate whether the differentiation of the surviving cells is truly dependent upon a direct TRAIL signal, in some experiments, the supernatants of His-Pept. (control)- and TRAIL-treated cells were
harvested and filtered (0.4 µm) after 24 hours of culture. Incubation of HL60 cells with control supernatant did not result in any modulation of maturative markers. On the other hand, a significant increase of CD14 and CD11b surface expression, as well as induction of apoptosis was observed upon 24 hours-incubation of HL60 cells with the supernatant derived from TRAIL-treated cultures (Figure 4A-B). However, such effects were abrogated by pre-incubating the TRAIL-treated supernatant with the TRAIL-R1-Fc chimeric protein, supporting a direct and specific role of residual TRAIL in the differentiation process (Figure 4A-B). This conclusion was further strengthened by the observation that treatment of HL-60 cells with LY294002, a pharmacological inhibitor of the PI 3-kinase/Akt survival pathway, induced a significant increase in the percentage of apoptosis without inducing any maturative effect in the surviving HL-60 cells (Figure 4A-B).

TRAIL-treated HL-60 cells were next analyzed by a functional assay, consisting in the evaluation of the phagocytic activity of solid particles. The phagocytic activity in TRAIL-treated cells was significantly ($P<0.05$) increased, as demonstrated by the higher incorporation of microbeads-FITC with respect to the untreated cells and/or cells treated with His-Pept., as evaluated by flow cytometry (Figure 4C).

**TRAIL-induced monocytic maturation of HL-60 cells requires the activation of the caspase cascade**

We have recently demonstrated that TRAIL activates both effector caspases and NOS pathways in the K562 erythroleukemic cell line and that both pathways contribute to the cytotoxicity of TRAIL on these leukemic cells (29). Moreover, it has been shown that certain types of AML can be induced to differentiate along the monocytic lineage by NO (35). Therefore, in the next group of experiments, we sought to investigate whether these pathways were involved also in the maturational effects induced by TRAIL in the myeloblastic HL-60 cell line.

The activity of the effector caspase subgroup (including caspase 3) and the ICE subgroup (including caspase 1) was assessed at different time points after treatment with either control His.-Pept or with TRAIL. While no activation of the ICE subgroup was observed upon treatment with TRAIL, activity of caspase 3 subgroup showed a
significant \((P<0.01)\) and persistent increase (Figure 5A) respect to untreated and/or His. Pept.-treated cells. The activation of caspase 3 subgroup was independently demonstrated by using a fluorimetric marker revealed by flow cytometry (Figure 5B).

The role of the caspase pathway in TRAIL-mediated maturation of HL-60 cells was next investigated by using selective pharmacological inhibitors. In this set of experiments, cells were pre-incubated with each inhibitor for 45 minutes, followed by the co-incubation of TRAIL for additional 24-72 hours. After treatment with TRAIL, cytotoxicity and degree of maturation were examined. Cell viability and expression of surface antigens were not affected by any of the inhibitors, used at indicated concentrations, in control HL-60 cells (data not shown). Incubation of HL-60 cells with the broad inhibitor of effector caspases, z-VAD-fmk, completely abrogated the TRAIL-induced apoptosis \((P<0.01)\) (Figure 6A) and almost completely prevented \((P<0.01)\) the TRAIL maturational effect (Figure 6B). On the other hand, the NOS inhibitor, L-NAME, did not affect \((P>0.1)\) the degree of maturation along the monocytic lineage, thus suggesting that effector caspases play a crucial role in TRAIL-mediated maturation, while the NO pathway is not involved in this process.

It has been previously shown that members of the TNF superfamily activate two main signal transduction pathways. The type I pathway is mediated by high levels of caspase 8, which directly activates effector caspases. On the other hand, the type II pathway is mediated by mitochondrial dysfunction, which precedes activation of caspase 9 \((36)\). Therefore, the maturation activity of TRAIL was evaluated also in the presence of selective inhibitors for caspase 8 and caspase 9. As shown in Figure 6, z-IETD-fmk, a selective caspase 8 inhibitor, significantly \((P<0.01)\) reduced the cytotoxic activity of TRAIL (Figure 6A) and was as efficient as z-VAD-fmk in blocking \((P<0.01)\) the TRAIL-induced maturation along the monocytic pathway (Figure 6B). On the other hand, z-LEHD-fmk, a selective caspase 9 inhibitor, was unable to significantly prevent TRAIL-mediated cytotoxicity and maturative effect (Figure 6A-B).

**The maturational effect of TRAIL is mediated by TRAIL-R1**

It should be emphasized that an extreme complexity characterizes the expression and function of TRAIL receptors (reviewed in 4). In fact, at least five TRAIL receptors
have been described so far. TRAIL-R1 (DR4) and TRAIL-R2 (DR5) transduce apoptotic signals upon binding of TRAIL, while TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2), as well as osteoprotegerin, are homologous to DR4 and DR5 in their cysteine-rich extracellular domain but lack intracellular death domain and apoptosis inducing capability. Although HL-60 cells expressed the mRNA of all transmembrane TRAIL receptors (TRAIL-R1, -R2, -R3 and -R4) (Table 1), flow cytometry analysis showed detectable surface levels of TRAIL-R1 and TRAIL-R2 expression coupled to very low or undetectable surface expression of TRAIL-R3 and TRAIL-R4 (Table 1). Therefore, to elucidate whether the maturational effects of TRAIL on HL-60 cells were specifically mediated by one or more TRAIL receptors, HL-60 cells were challenged with agonistic polyclonal anti-TRAIL-R1, -R2, -R3 and -R4 antibodies, which mimic the interaction between TRAIL and each TRAIL-R, without cross-reacting among each other (37).

Remarkably, treatment of HL-60 with anti-TRAIL-R1, but not with anti-TRAIL-R2, anti-TRAIL-R3 or anti-TRAIL-R4, induced a significant ($P<0.05$) increase of both apoptosis (Figure 7A) and CD14 (Figure 7B) surface expression. The biological activity of anti-TRAIL-R1 antibody was significantly lower ($P<0.05$) than that of recombinant TRAIL, likely due to their differential ability to induce TRAIL-R1 oligomerization.

**TRAIL induces maturation along the monocytic lineage also in primary normal CD34 derived myeloid cells**

In the last group of experiments, we have investigated whether TRAIL affected the maturation of primary normal myeloid cells. For this purpose, we have set up serum-free liquid cultures of CB CD34$^+$ hemopoietic progenitors supplemented with SCF + GM-CSF. Cells were monitored for phenotypic expression of myeloid maturative surface antigens every two days and TRAIL was typically added in culture between day 4 and day 8, when the cells still showed low expression of CD14. At this time point, primary normal myeloid cells expressed the mRNA for all TRAIL receptors and at flow cytometry, a dim expression of TRAIL-R1 and TRAIL-R2 and TRAIL-R3 was clearly observed while TRAIL-R4 was undetectable (Table 1). Thus, with the exception of surface TRAIL-R3, the phenotypic pattern of primary myeloid cells at this culture time (days 4-8) resembled that of HL-60 myeloblastic cell line (Table 1). In agreement with
the data obtained on the HL-60 cell line, the addition of TRAIL for 3 days significantly ($P<0.01$) increased the surface expression of both CD14 (from 15±7% to 33±6 mean±SD, \( n = 6 \) independent experiments) and CD11b (from 26±8%, to 47±9, mean±SD, \( n = 6 \) independent experiments) antigens with respect to untreated and/or control cells treated with His.-Pept. (Figure 8A). It is particularly remarkable, however, that TRAIL did not induce any significant cytotoxicity on primary normal myeloid cells, as evaluated in terms of apoptosis (from 15±4 to 20±6, mean±SD, \( n = 6 \) independent experiments) and viable cell counts (from 126x10^4 to 132x10^4, mean±SD, \( n = 6 \) independent experiments).

At light microscopy examination, untreated and/or His-Pept.-treated control cultures were characterized by an heterogenous population of cells comprising monoblasts, granulocyte precursors, monocytes, and rare macrophages (Figure 8B). The frequency of monocytes and macrophages in control cultures varied from 19 to 40% in the different experiments performed. In TRAIL-treated cultures, the cell population was still heterogeneous, but cells with morphological features of mature monocytes and macrophages were more easily detectable and their frequency ranged from 35 to 58%.
Discussion

We have here shown for the first time that, besides inducing a marked cytotoxicity on HL-60, TRAIL promotes maturation of the surviving cells along the monocytic lineage, as shown by combining phenotypic, morphological and functional analyses. The possibility that monocytic maturation was the consequence of stress factors released by apoptotic HL-60 cells cannot be completely excluded but is unlikely on the basis of experiments performed by using the culture supernatant of apoptotic HL-60 cells that was unable to induce monocytic maturation when added to viable cells in the presence of TRAIL-R1-Fc. Moreover, the induction of apoptosis by LY294002 a pharmacological compound interfering with the PI 3-kinase/Akt survival pathway did not induce any monocytic maturation in HL-60 cells. It is particularly remarkable that similar maturational effects were observed also in TRAIL-treated primary normal myeloid cells in the absence of cytotoxicity. Therefore, the ability of TRAIL to promote maturation along the monocytic pathway is not confined to the HL-60 experimental cell model, but it also involves primary normal myeloid cells. Moreover, the fact that the maturational activity of TRAIL in primary myeloid cells took place in the absence of cytotoxicity strongly suggests that a major physiological role of the TRAIL/TRAIL receptor system in hemopoiesis is to promote normal monocytic development. It should also be emphasized that this represents the first demonstration of a positive regulative effect of TRAIL on primary normal cells, while previous studies of our and other groups have demonstrated inhibitory effects of TRAIL on primary normal immature erythroblasts (19, 20) in the absence of cytotoxicity on normal myeloid cells (11).

The ability of TRAIL to promote monocytic differentiation of the HL-60 leukemic cell line, besides inducing cytotoxicity, envisions an additional role of TRAIL as an antineoplastic agent, at least for certain types of acute myeloid leukemias. In fact, inducing mortality by terminal differentiation represents an alternative approach to cytodestruction of cancer cells by conventional antineoplastic agents with important biological implications. In fact, it indicates that the malignant state is not an irreversible one and suggests that certain cancers may eventually be treated with agents that initiate terminal maturation, presumably with less morbidity than that produced by
cytodestructive agents (38). In this respect, retinoid acids are well known inducers of granulocytic differentiation of primary acute promyelocytic leukemia (APL) blasts and leukemic cell lines, apparently via transcriptional regulation of genes critical to this process (39). In fact, both retinoids and vitamin D3 interact with nuclear receptors, members of the steroid/thyroid hormone receptor superfamily of transcription factors (40). These are ligand-inducible trans regulators that modulate the transcription of genes, which play a critical role in the control of cell growth and differentiation by interacting with retinoic acid or vitamin D3 cis-acting DNA responsive elements (39, 40). However, while some retinoids are currently used in the treatment of APL, the M3-type of AML, agonists able to induce monocytic differentiation in vitro, such as vitamin D3, have not demonstrated efficacy in clinical trials performed in leukemic patients affected by different types of AML, mainly due to a secondary hypercalcemia which limited the dose of this agent that could be administered (41). Interestingly, it has been recently proposed that one of the mechanisms of action of retinoic acid in APL is the induction of TRAIL expression in cells differentiating along the granulocytic lineage (42). It has also been shown that HL-60 cells become progressively more resistant to TRAIL cytotoxicity as ATRA-induced granulocytic differentiation proceeds (43).

Our present study suggests that a therapeutic regimen including TRAIL would optimize the anti-leukemic activity against neoplastic cells by a twofold mechanism: cytotoxicity and induction of differentiation along the monocytic lineage. In this respect, TRAIL has garnered the most interest therapeutically, as several studies have demonstrated in vivo tumoricidal activity in animal models without inducing significant toxicity in both mice (44, 45) and nonhuman primates (46). Moreover, recombinant TRAIL synergizes with conventional chemo/radiotherapy in inducing cytotoxicity also in acute leukemias (37, 47-49), which lack a functional p53 wild-type or over-express Bcl-2 or MDR genes.

We have also started to explore the mechanisms underlying the maturational activity of TRAIL by demonstrating that the activation of effector caspases plays an essential role in this process. These data are in agreement with previous studies that have shown that the caspase activation in intact cells does not necessarily lead to cell death and argue for a checkpoint in the apoptotic pathway downstream of caspases. In particular, it
has been recently demonstrated that the terminal differentiation of erythroblasts requires a transient activation of caspases (21), thus indicating that the caspase family of proteases mediates a broader range of biological activities then originally thought, including the activation/proliferation of quiescent T lymphocytes (50, 51). Interestingly, two distinct caspase-dependent pathways have been described in response to CD95 ligand (36, 52), the member of the TNF superfamily showing the closest aminoacid structure to TRAIL. The type I pathway triggers the activation of large amounts of caspase-8 followed by the rapid cleavage of caspase-3 prior to loss of mitochondria transmembrane potential (Δψm). In the type II pathway, low concentrations of caspase 8, insufficient to allow an effective downstream activation of caspase 3, induce loss of Δψm. This, in turn, induces the release of cytocrome C and procaspase 9 from mitochondria, its activation in the cytosol and the activation of caspase 3 (36, 52).

We could demonstrate that in HL-60 cells, z-IETD-fmk, a selective pharmacological inhibitor of caspase 8, almost completely reproduced the ability of z-VAD-fmk, a broad inhibitor of effector caspases, to block the TRAIL-mediated cytotoxicity and maturational effects. On the other hand, z-LEHD-fmk, a selective pharmacological inhibitor of caspase 9, was unable to interfere with TRAIL biological activities. These findings clearly indicate that the type II intrinsic pathway, which has been mainly involved in the induction of apoptosis (36), does not play a role in the maturational effects of TRAIL. Theoretically, since TRAIL preferentially triggers the type I pathway in leukemic HL-60 cells, TRAIL + chemotherapeutic drugs might substantially enhance the anti-leukemic activity of conventional chemotherapy in hematological malignancies (36, 52).

The experiments performed with agonistic antibodies have indicated that, although both TRAIL-R1 and -R2 were expressed on the surface of HL-60 cells, only TRAIL-R1 induced maturation along the monocytic lineage. We have not used these agonistic antibodies in primary normal myeloid cultures due to the limited number of cells. However, we have observed that TRAIL-mediated maturation only took place in 4-8 day cultures, when primary myeloid cells expressed surface TRAIL-R1, -R2 and -R3. On the other hand, no changes in the surface expression of CD14 and CD15 were observed at later culture times (days 18-22), when TRAIL-R3 was the only TRAIL-R
expressed, as also shown by other authors (11 and data not shown). Thus, TRAIL-R1 likely plays an important role in mediating monocytic maturation possibly by activating effector caspases also in primary cells. Moreover, the coexistence of TRAIL-R3 with -R1 and -R2 on the surface of primary normal myeloid cells likely protect these cells from apoptosis.

In conclusion, the findings derived from this study might have important implications in understanding the biology of the TRAIL/TRAIL receptor system in both normal and leukemic hematopoiesis. In fact, our data disclose a novel physiological role for TRAIL as a positive regulator of monocytic maturation. Moreover, the dichotomous effect of TRAIL on malignant cells (early induction of apoptosis and maturation of the surviving cells) might have therapeutic implications for the treatment of acute myeloid leukemias and possibly of other hematological malignancies.
References


Figure Legends

Figure 1. Evaluation of the cytotoxic activity of human recombinant TRAIL on HL60 cells. Dose dependent effect of TRAIL on apoptosis quantitatively evaluated by flow cytometry after PI staining. Cells were cultured for 24 hours with the indicated concentrations of TRAIL. Data represent the mean±SD of five independent experiments performed in duplicate.

Figure 2. Phenotypic characterization of untreated and TRAIL-treated HL60 cells by immunofluorescence staining revealed by flow cytometry. A, Representative analysis of surface CD33, CD15, CD14 and CD11b performed at 24 hours of TRAIL-treatment (0.2 µg/ml). Analyses were performed by gating viable cells. The control (unshadowed) histograms represent the background fluorescence obtained from the staining of the same cultures with isotype-matched control MoAbs. In some panels, the unshadowed histograms are not visible since are completely overlapped by the shadowed histograms. The shift of the shadowed histogram along the X axis illustrates the induction of CD14 and the increased level of CD11b in a subpopulation of the TRAIL-treated culture. Data shown are from a single experiment representative of eight independent experiments with similar results. B, Dose dependent effect of TRAIL on surface CD14 expression, evaluated by flow cytometry and reported as percentage of CD14 positive cells. Data represent the mean±SD of five independent experiments performed in duplicate.

Figure 3. Morphologic features of untreated and TRAIL-treated HL60 cells. HL60 cultures were left untreated or treated for 72 h with TRAIL (0.2 µg/ml). After removing dead cells from the culture, cells were either cytocentrifuged and stained with May-Grunwald-Giemsa solution (A), or processed for transmission electron microscopy (B). In A, cells with monocytic morphology are indicated by asterisks. Representative fields of five separate experiments are shown. Original magnification is 400X in A, and 7000X in B.
Figure 4. Specificity of TRAIL-induced CD14 expression in HL60 cells. After 24 hours of the indicated treatments, apoptosis (A) was determined by PI staining and percentages of cells expressing CD14 (B) were evaluated by flow cytometry. Sup., supernatant derived from either untreated or TRAIL-treated HL60 cultures. Data represent the means±SD of three-to-five separate experiments performed in duplicate. C, Evaluation of phagocytosis ability of untreated and TRAIL-treated HL60 cells determined by flow cytometry measure of fluorescent latex microbeads incorporation. Percentage of fluorescent cells is indicated. A representative of four separate experiments is shown.

Figure 5. Evaluation of TRAIL-induced caspase activity in HL60. Cells were treated with TRAIL (0.2 µg/ml) for the indicated times. A, Caspase activity was evaluated on cell lysates by using either CPP32 or ICE substrates. Data are expressed as percentage of control (His. peptide-treated) cells. Data represent the means±SD of four independent experiments performed in duplicate. B, Caspase activation induced by TRAIL, in the presence or absence of z-VAD-fmk inhibitor of effector caspases, has been evaluated by flow cytometry following incubation with CaspACE FITC-VAD-FMK in situ marker. Data are expressed as percentage of positive (fluorescent) cells. Analysis has been performed after 6 hours of TRAIL-treatment by gating viable cells. Data represent the means±SD of four independent experiments performed in duplicate.

Figure 6. Effect of pharmacological inhibitors on TRAIL-mediated cytotoxicity and CD14 induction in HL60 cells. Cultures were left untreated or treated for 24 hours with TRAIL in absence (vehicle) or in presence of the following inhibitors: L-NAME, inhibitor of NOS; z-VAD-fmk, inhibitor of effector caspases; z-IETD-fmk, specific inhibitor of caspase 8; z-LEHD-fmk, specific inhibitor of caspase 9. A, Percentage of apoptosis quantitatively evaluated by flow cytometry after PI staining; B, percentage of cells expressing surface CD14, evaluated by flow cytometry. Data represent the means±SD of three separate experiments performed in duplicate.
**Figure 7. Effect of agonist Abs anti-TRAIL receptors on HL60 viability and CD14 induction.** Cultures were left untreated or treated with TRAIL (0.2 µg/ml) or Ab anti-TRAIL receptors (TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4) for 24 hours. A, Apoptosis quantitatively evaluated by flow cytometry after PI staining. B, Percentage of cells expressing surface CD14, determined by flow cytometry. Data represent the means±SD of three separate experiments performed in duplicate.

**Figure 8. Effect of TRAIL on committed myelo-monocytic precursors.** At days 4-8, serum-free liquid cultures of CB CD34+ hemopoietic progenitors supplemented with SCF + GM-CSF, were left untreated or incubated with TRAIL for additional 3 days. A, Phenotypical characterization of untreated and TRAIL-treated cultures by staining with anti-CD14 and anti-CD11b MoAbs. Shadowed histograms represent cells stained with MoAbs specific for the indicated antigens, while unshadowed histogram represents control cells, stained with control MoAbs. Percentages of positive cells are indicated in each panel. Data shown are from a single experiment representative of six independent experiments with similar results. B, Morphologic features of untreated and TRAIL-treated cultures revealed by staining with May-Grunwald-Giemsa solution. Different cell types are indicated (Mo=monocyte, Ma=macrophage, Gp=granulocyte precursor, Mn=monoblast). Representative fields of six separate experiments are shown. Original magnification is 400X.
Figure 1

The graph shows the percentage of apoptosis in response to different concentrations of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand). The x-axis represents the TRAIL concentration in ng/ml, while the y-axis represents the percentage of apoptosis. The data indicates a dose-dependent increase in apoptosis with increasing TRAIL concentration.
Figure 2A

<table>
<thead>
<tr>
<th>Untreated</th>
<th>TRAIL</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD33</td>
<td></td>
</tr>
<tr>
<td>CD15</td>
<td></td>
</tr>
<tr>
<td>CD14</td>
<td></td>
</tr>
<tr>
<td>CD11b</td>
<td></td>
</tr>
</tbody>
</table>

Mean Fluorescence Intensity
Figure 2B

![Graph showing the percentage of CD14 positive cells against TRAIL concentration (ng/ml). The x-axis represents TRAIL concentration in ng/ml (0, 20, 50, 100, 500, 2000) and the y-axis represents the percentage of CD14 positive cells. The bars indicate the mean with error bars representing the standard deviation.](image-url)
Figure 3A

Untreated  TRAIL

*  *

From www.bloodjournal.org by guest on August 16, 2017. For personal use only.
Figure 3B

Untreated

TRAIL
Figure 4A

Percentage of apoptosis
Figure 4B

Percentage of CD14 positive cells
Figure 4C

Untreated

TRAIL

Mean Fluorescence Intensity

5%

21%
Figure 5A
Figure 5B

Untreated  TRAIL  TRAIL+z-VAD-fmk

Relative Cell Number

Mean Fluorescence Intensity

1%  37%  3%
Figure 6A

TRAIL

- z-LEHD-fmk
- z-IETD-fmk
- z-VAD-fmk
- L-NAME
- vehicle
- untreated

Percentage of apoptosis

0 10 20 30 40 50 60 70
Figure 6B

Percentage of CD14 positive cells
Figure 7A

![Bar graph showing percentage of apoptosis for different treatments](image-url)
Figure 7B

Percentage of CD14 positive cells

TRAIL
anti-TRAIL-R4
anti-TRAIL-R3
anti-TRAIL-R2
anti-TRAIL-R1
Nil
Figure 8A

CD14

Untreated

CD11b

TRAIL

Mean Fluorescence Intensity
Figure 8B
**Table 1**

**Table 1.** Analysis of TRAIL-receptor expression.

<table>
<thead>
<tr>
<th>Analyses</th>
<th>HL-60</th>
<th>Primary myeloid cells</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RT-PCR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRAIL-R1</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>TRAIL-R2</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>TRAIL-R3</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>TRAIL-R4</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>Flow-cytometry</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRAIL-R1</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>TRAIL-R2</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>TRAIL-R3</td>
<td>undetectable</td>
<td>14</td>
</tr>
<tr>
<td>TRAIL-R4</td>
<td>undetectable</td>
<td>undectable</td>
</tr>
</tbody>
</table>

Data are representative of three separate experiments performed in duplicate. ^aData are expressed as MFI. SD were comprised within 15% of the means and are omitted for clarity.
TNF-related apoptosis-inducing ligand (TRAIL) induces monocytic maturation of both leukemic and normal myeloid precursors via a caspase-dependent pathway

Paola Secchiero, Arianna Gonelli, Prisco Mirandola, Elisabetta Melloni, Loris Zamai, Claudio Celeghini, Daniela Milani and Giorgio Zauli